Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF).

Persistent atrial fibrillation (AFib) is a condition where an irregular heart rhythm lasts for more than a week.

The company said that it is the only trial to study using PFA as frontline therapy in patients with this form of AF.

Outcomes of ablation with the FARAPULSE PFA System—a nonthermal treatment in which electric fields selectively ablate heart tissue—will be compared to outcomes following the use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with ...